Loading...
•
Sep 30, 2025
LifeMD Q3 2025 Earnings Report
LifeMD reported third-quarter results with double-digit revenue growth and reduced net loss.
Key Takeaways
LifeMD delivered a solid Q3 with 13% revenue growth, improved adjusted EBITDA, and a significant reduction in net loss. The company strengthened its balance sheet by paying off all debt and exited its WorkSimpli stake to focus on core telehealth operations.
Revenue by Segment
Forward Guidance
LifeMD expects Q4 2025 revenue between $45M–$46M and adjusted EBITDA between $3M–$4M as a standalone telehealth business.
Positive Outlook
- Transition to a pure-play telehealth platform completed
- Debt fully paid off, improving financial position
- Regulatory approval of 503-A compounding pharmacy
- Strong momentum in subscriber growth and new launches
- Telehealth business returned to sequential growth
Challenges Ahead
- Net loss remained, despite narrowing
- Gross margin declined year-over-year
- Continued headwinds in weight management market
- No geographic revenue breakdown provided
- Q4 guidance reflects reduced scale post-WorkSimpli divestiture
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...